{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001873835","name":"Immix Biopharma, Inc.","summary":"Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on chimeric antigen receptor cell therapy (CAR-T) for light chain (AL) Amyloidosis and other serious diseases. Its lead candidate, NXC-201, is being evaluated in U.S. Phase 1b/2 NEXICART-2 and ex-U.S. NEXICART-1 clinical trials. NXC-201 has received FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations, as well as European Commission Orphan Drug Designation for AL Amyloidosis. The company's N-GENIUS platform underpins its cell therapy development pipeline.","people":[],"products":[{"name":"NXC-201","type":"platform","description":"Next-generation sterically-optimized CAR-T cell therapy candidate targeting relapsed/refractory AL Amyloidosis and other serious diseases, in Phase 1b/2 clinical trials."},{"name":"N-GENIUS Platform","type":"platform","description":"In-licensed platform with evidence capture engine, proprietary EXPAND technology, and novel binding scaffold generation engine used to design and manufacture CAR-T candidates."}],"partnerships":[{"partner_name":"California Institute for Regenerative Medicine (CIRM)","partnership_type":"strategic","description":"Awarded an $8 million grant to support clinical development of NXC-201 for relapsed/refractory AL Amyloidosis.","start_date":null},{"partner_name":"Memorial Sloan Kettering Cancer Center","partnership_type":"development","description":"Lead clinical site for the NEXICART-2 U.S. Phase 1b/2 trial of NXC-201.","start_date":null},{"partner_name":"Morgan Stanley & Co. LLC","partnership_type":"strategic","description":"Representative underwriter for the December 2025 public offering raising approximately $100 million in gross proceeds.","start_date":null}],"affiliations":[],"origin":{"leaf":"fd38e212aebbda704d946945b93055b0ba8368afe5a0d5c12b8883cdc1f980e0","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"7b5dfd5c607d7734da8c8ec15db98c20b7a31e4e77247f298eee0d825096425d","parent":"60c6ab8769949f3f0cb600c81d8263f57b9e1bee3acd3257f68fa737e8783bbe","source":"0001493152-26-012714","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":403,"hourly_limit":500,"remaining":97,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}